20cm速递｜创新药板块小幅回调，科创创新药ETF国泰（589720）回调0.4%，近20日净流入超8亿元

Group 1 - The core viewpoint is that despite some adjustments in the innovative drug sector, China's global competitiveness in innovative drugs continues to strengthen, with ongoing international expansion and commercialization profitability remaining intact [1] - In the past two years, there has been a significant increase in the number and value of license-out transactions for Chinese innovative drugs, reaching a record high [1] - According to statistics from Guojin Securities and Yibao Magic Cube, by 2025, the number of new drug license-out transactions in China is expected to reach 158, with a total transaction scale of $135.7 billion and an upfront payment scale of $7 billion, marking the highest figures in nearly a decade [1] Group 2 - The prosperity of outbound business development (BD) is expected to significantly boost the short-term performance of innovative drug companies and promote the international development process of domestic new drugs, leading to substantial long-term value enhancement [1] - The Guotai Innovation Drug ETF (589720) tracks the Science and Technology Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on the research, development, and production of innovative drugs [1] - The index emphasizes the high growth and innovation of the biopharmaceutical industry, reflecting the performance and market value of companies involved in new drug research and development [1]